Last month, the World Health Organisation also recommended against remdesivir as a treatment for COVID patients because evidence supporting its use was lacking. Limited results earlier were announced via news releases, showing that hospitalised COVID patients treated with baricitinib and remdesivir recovered one day faster than those who had received remdesivir alone. Both baricitinib and dexamethasone are thought to act by tamping down excessive inflammation, which drives many severe cases of COVID. The trial enrolled more than 1,000 hospital patients with COVID, all of whom received remdesivir. Dexamethasone, unlike baricitinib, has been shown in studies to curb mortality in seriously ill COVID patients.

Source: bd News24 December 14, 2020 03:33 UTC